Cargando…

Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report

Epithelial ovarian cancer is extremely difficult to treat due to its high recurrence rate and acquired tolerance to chemotherapy. Immune checkpoint inhibitors (ICIs) are expected to be promising solutions for treatment failure. However, the low response rate to a single ICI agent was demonstrated in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Shaoxing, Sun, Wenjie, Xiang, Qingming, Yang, Chunxu, Chen, Min, Mei, Zijie, Yang, Hui, Zeng, Zihang, Cao, Hong, Tian, Yueli, Zhang, Gong, Qiu, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670358/ https://www.ncbi.nlm.nih.gov/pubmed/34338238 http://dx.doi.org/10.1097/CAD.0000000000001178

Ejemplares similares

A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy
por: Yang, Hui, et al.
Publicado: (2021)

The impact of bone marrow irradiation dose on acute haematologic toxicity in cervical cancer patients treated with concurrent chemoradiotherapy
por: Chen, Min, et al.
Publicado: (2023)

Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts
por: Zeng, Zihang, et al.
Publicado: (2022)

ZMIZ1 Preferably Enhances the Transcriptional Activity of Androgen Receptor with Short Polyglutamine Tract
por: Li, Xiaomeng, et al.
Publicado: (2011)

Immunotherapeutic Agents for Intratumoral Immunotherapy
por: Shyr, Chih-Rong, et al.
Publicado: (2023)

Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study
por: Yang, Hui, et al.
Publicado: (2021)

Application Of Adoptive Immunotherapy In Ovarian Cancer
por: Yang, Siyu, et al.
Publicado: (2019)

Immunotherapy for Lung Cancers
por: Ho, Ming-Yi, et al.
Publicado: (2011)

Recent Progress of Nanoscale Metal-Organic Frameworks in Cancer Theranostics and the Challenges of Their Clinical Application
por: Sun, Wenjie, et al.
Publicado: (2019)

Diffuse midline glioma treated with epigenetic agent-based immunotherapy
por: Jing, Linkai, et al.
Publicado: (2023)

Immunotherapies in ovarian cancer
por: García-Martínez, Elena, et al.
Publicado: (2020)

Immunotherapy in Ovarian Cancer
por: Siminiak, Natalia, et al.
Publicado: (2022)

Nanomedicine Strategies for Heating “Cold” Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC
por: Yang, Yuqi, et al.
Publicado: (2022)

Dropouts From Sublingual Immunotherapy and the Transition to Subcutaneous Immunotherapy in House Dust Mite-Sensitized Allergic Rhinitis Patients
por: Chen, Huan, et al.
Publicado: (2022)

Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application
por: Xie, Hongyu, et al.
Publicado: (2021)

Exosomes: A potential tool for immunotherapy of ovarian cancer
por: Gong, Xiangjin, et al.
Publicado: (2023)

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
por: Yang, Chang, et al.
Publicado: (2020)

Leveraging various extracellular matrix levels to assess prognosis and sensitivity to immunotherapy in patients with ovarian cancer
por: Huang, Youqun, et al.
Publicado: (2023)

Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer
por: Gao, Lingling, et al.
Publicado: (2023)

Suppressive stroma-immune prognostic signature impedes immunotherapy in ovarian cancer and can be reversed by PDGFRB inhibitors
por: Yang, Dong, et al.
Publicado: (2023)

Ovarian Carcinosarcoma and Response to Immunotherapy
por: Daniyal, Muhammad, et al.
Publicado: (2023)

Development of a risk model based on autophagy-related genes to predict survival and immunotherapy response in ovarian cancer
por: Chen, Yuwei, et al.
Publicado: (2023)

Development of a Plastic Embedding Method for Large-Volume and Fluorescent-Protein-Expressing Tissues
por: Yang, Zhongqin, et al.
Publicado: (2013)

Comprehensive multi-omics analysis reveals m7G-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma
por: Zhang, Yiming, et al.
Publicado: (2023)

Systematic Analyses of a Chemokine Family-Based Risk Model Predicting Clinical Outcome and Immunotherapy Response in Lung Adenocarcinoma
por: Chen, Jiarui, et al.
Publicado: (2021)

The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factors
por: Xiang, Mengqi, et al.
Publicado: (2022)

X-box Binding Protein 1 is a Potential Immunotherapy Target in Ovarian Cancer
por: Jiang, Yanhui, et al.
Publicado: (2022)

Resveratrol analog, triacetylresveratrol, a potential immunomodulator of lung adenocarcinoma immunotherapy combination therapies
por: He, Jian, et al.
Publicado: (2023)

Strong emerging rationale for combining oncogene-targeted agents with immunotherapy
por: Yang, Yan, et al.
Publicado: (2013)

Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer
por: Yang, Dong, et al.
Publicado: (2023)

The characteristics of oviposition and hormonal and gene regulation of ovarian follicle development in Magang geese
por: Qin, Qingming, et al.
Publicado: (2013)

Systematic Profiling of Immune Risk Model to Predict Survival and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
por: Liu, Xingyu, et al.
Publicado: (2020)

c-Fos Repression by Piwi Regulates Drosophila Ovarian Germline Formation and Tissue Morphogenesis
por: Klein, Jonathon D., et al.
Publicado: (2016)

Adoptive immunotherapy against ovarian cancer
por: Mittica, Gloria, et al.
Publicado: (2016)

Immunotherapy Advances for Epithelial Ovarian Cancer
por: Hartnett, Erin G., et al.
Publicado: (2020)

Ovarian Cancer Immunotherapy and Personalized Medicine
por: Morand, Susan, et al.
Publicado: (2021)

Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia
por: YANG, XIN-YU, et al.
Publicado: (2015)

Chronic inflammation, cancer development and immunotherapy
por: Wen, Yalei, et al.
Publicado: (2022)

RESEARCH ON VULNERABILITY RISK ASSESSMENT OF COLLABORATIVE INNOVATION NETWORK DRIVEN BY MULTI-AGENT EMOTIONAL BEHAVIOR
por: Yang, Tao, et al.
Publicado: (2022)

SETD2 mediates immunotherapy and radiotherapy efficacy via regulating DNA damage responses and genomic stability in lung adenocarcinoma
por: Zeng, Zihang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ku6phjr57miontp77a0ad99q0n